Repeated Dose Study for the Investigation of Heritability of and Genetic Influences on Drug Pharmacokinetics

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

117 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-12-31

Study Completion Date

2013-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This human pharmacokinetic study investigates, whether processes of drug metabolism and transport are determined by genetic or hereditary factors. Therefore, approved drugs are applied to twins and metabolism and transport processes are investigated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetics of the Basel Phenotyping Cocktail Combination Capsule

NCT03247699

CYP450 Phenotyping

COMPLETED NA

Determination of Drugs and Their Metabolites in Hospitalized Patients

NCT01702545

Neoplasms

UNKNOWN

CYP1A2 and ADORA2A Genotypes and Endurance Performance.

NCT06547307

Healthy

RECRUITING NA

Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy Subjects

NCT01934166

Renal Impairment

COMPLETED PHASE1

Effect of Polymorphisms in the Adenosine a2a Receptor Gene and AMPD2 Gene on Adenosine-Induced Vasodilation and Reactive Hyperemia

NCT00253929

Blood Flow in Healthy Volunteers

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Drug Biotransformation Membrane Transport

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Drug application

Two treatment periods:

Treatment period 1:

three sequential oral and i.v. doses of 5 mg Metoprolol, 50 mg Talinolol, 2.5 mg Torsemide, 0.2 mg Midazolam and 50 mg Caffeine. At least 1 week of wash out between drug application

Treatment period 2:

combined application of a single oral dose of 2.5 mg Talinolol, 0.25 mg Torsemide, 5 mg Pravastatin, 1 mg Midazolam and 5 mg Codeine.

Treatment period 2 may take place after or before treatment period 1 with a time interval of at least 1 week

Group Type EXPERIMENTAL

Codeine

Intervention Type DRUG

Treatment period 2:

5 mg Codeine once

Midazolam

Intervention Type DRUG

Treatment period 1:

0.2 mg Midazolam 3x

Treatment period 2:

1 mg Midazolam once

Pravastatin

Intervention Type DRUG

Treatment period 2:

5 mg Pravastatin once

Torsemide

Intervention Type DRUG

Treatment period 1:

2.5 mg Torsemide 3x

Treatment period 2:

0.25 mg Torsemide once

Talinolol

Intervention Type DRUG

Treatment period 1:

50 mg Talinolol 3x

Treatment period 2:

2.5 mg Talinolol once

Caffeine

Intervention Type DRUG

Treatment period 1:

50 mg Caffeine 3x

Metoprolol

Intervention Type DRUG

Treatment period 1:

5 mg Metoprolol 3x

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Codeine

Treatment period 2:

5 mg Codeine once

Intervention Type DRUG

Midazolam

Treatment period 1:

0.2 mg Midazolam 3x

Treatment period 2:

1 mg Midazolam once

Intervention Type DRUG

Pravastatin

Treatment period 2:

5 mg Pravastatin once

Intervention Type DRUG

Torsemide

Treatment period 1:

2.5 mg Torsemide 3x

Treatment period 2:

0.25 mg Torsemide once

Intervention Type DRUG

Talinolol

Treatment period 1:

50 mg Talinolol 3x

Treatment period 2:

2.5 mg Talinolol once

Intervention Type DRUG

Caffeine

Treatment period 1:

50 mg Caffeine 3x

Intervention Type DRUG

Metoprolol

Treatment period 1:

5 mg Metoprolol 3x

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent obtained prior to study entry including informed consent for genetic research
* Both genders (male and female)
* Healthy adults aged ≥18 to \< 65 years
* Body weight of subjects of both genders not less than 50 kg and not more than 120 kg. BMI not less than 18 kg/m² and not greater than 33 kg/m²
* Willingness to meet the study instructions and to co-operate with the study personal
* No clinically relevant pathological findings in any of the investigations at the Screening visit. Minor deviations of laboratory values from the normal range may be accepted, if judged by the investigator to have no clinical relevance
* Female subjects will only be included if they have negative serum pregnancy test during screening and the willingness not to become pregnant during the entire study period by practicing reliable methods of contraception as specified in the respective protocol section.
* Dizygotic twins will only be included if both siblings are of the same gender, either male or female and triplets, quadruplets or other multiplets if at least two siblings are of the same gender
* Smokers will only be included if both siblings are smoking to a similar extend (+/- 10 cigarettes per day)

Exclusion Criteria

* Involvement in the planning and conduct of the study (applies to staff directly employed at the study site / department)
* Participation in a clinical study during the last 30 days or use of any other investigational or non-registered drug or vaccine during the study period or within 30 days preceding the first dose of study drugs
* Blood, plasma or thrombozyte donation during the last 30 days prior to application of the test drugs
* Age \< 18 years or \> 65 years
* Known pregnancy or lactation period
* Any relevant pathological findings in any of the investigations at the screening visit including significant abnormalities as result of the medical-screening-laboratory-analysis, especially of the liver and kidney related parameters.
* Any disease affecting liver or kidney or impairment of the liver or kidney-function
* Any cardiac disease in which use of beta-blockers or caffeine might be contraindicated.
* Bronchogenic asthma requiring constant drug treatment (stages 2 to 4 asthma)
* Known Raynaud's syndrome
* Any major acute disease or fever (Temp. \> 37.5 C)
* Any major gastrointestinal disease and any gastrointestinal disorder that is expected to significantly interfere with the pharmacokinetics of the study drug
* Gastrointestinal surgery which may interfere with the pharmacokinetics of the study drug (except appendectomy or herniotomy)
* Taking any medication within 7 days before or during the trial with the following exceptions: Single doses of mild analgesics (e.g. aspirin, paracetamol, ibuprofen) may have been taken except for the time from 6 hours prior to taking the test drug until 24 hours after taking the test drug. Oral contraceptive drug used will be documented but will not be an exclusion criterion. Other medication might be allowed on single case basis if considered necessary for the subject's safety and well-being.
* History of alcohol and/or drug addiction and/or any abusive use of medicaments and/or positive drug screen
* Any other findings that could compromise the safety of the participant or the quality of the study-results
* History of severe hypersensitivity reactions and anaphylaxis
* If hypersensitivity or allergic reactions to one of the IMPs is known so enrolment is possible but application of the concerned IMP must not be allowed in all siblings (e.g. allergy to sulphonamide prohibits specifically the application of torsemide)
* Clinically significant diseases as judged by the investigator
* Body temperature \> 37.5°C prior to drug application
* Known infection with HIV, Hepatitis B (HBsAg) or Hepatitis C
* Inability or unwillingness to avoid any intake of alcohol from 48h prior to until 72hours after IMP application
* Pregnancy (positive pregnancy test during screening and/or treatment)
* Lactation or unreliable contraception in female subjects with child-bearing potential
* Inability or unwillingness to provide informed consent and to abide by the requirements of the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes